Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.64 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166707 | 0.98 | CHRNB2 (0.66) | CHRNB2CHRNA4TRPV6KDM4EALDH1A1 | |
| Bromide SCHEMBL4171916 | 0.92 | SLC6A3 (0.58) | — | |
| SCHEMBL4168265 | 0.91 | SLC6A3 (0.59) | — | |
| SCHEMBL15800693 | 0.87 | CHRNB2 (0.77) | CHRNB2CHRNA4TRPV6KDM4EALDH1A1 | |
| Bromide SCHEMBL4174825 | 0.87 | SIGMAR1 (0.65) | KDM4EALDH1A1 | |
| SCHEMBL16026435 | 0.85 | CHRNB2 (0.85) | CHRNB2CHRNA4TRPV6KDM4EALDH1A1 | |
| SCHEMBL4169559 | 0.85 | SIGMAR1 (0.67) | KDM4EALDH1A1 | |
| SCHEMBL7194677 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4TRPV6KDM4EALDH1A1 | |
| SCHEMBL1305690 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4TRPV6KDM4EALDH1A1 | |
| SCHEMBL8306431 | 0.81 | CHRNB2 (0.72) | CHRNB2CHRNA4TRPV6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| EP-1981849-A1 | HETEROCYCLIC COMPOUNDS | LEK Pharmaceuticals D.D. (SI) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | CYP51A1, DHCR7, LSS | CHRNB2 628/4885CHRNA4 416/4885TRPV6 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.